Stockreport

Lineage Cell price target lowered to $2 from $3 at D. Boral Capital [Yahoo! Finance]

Lineage Cell Therapeutics, Inc.  (LCTX) 
PDF D. Boral Capital lowered the firm's price target on Lineage Cell Therapeutics ( LCTX ) to $2 from $3 and keeps a Buy rating on the shares. The firm adjusted the company [Read more]